High-Throughput Sequencing of mGluR Signaling Pathway Genes Reveals Enrichment of Rare Variants in Autism
Open accessAbstract
Identification of common molecular pathways affected by genetic variation in autism is important for understanding disease pathogenesis and devising effective therapies. Here, we test the hypothesis that rare genetic variation in the metabotropic glutamate-receptor (mGluR) signaling pathway contributes to autism susceptibility. Single-nucleotide variants in genes encoding components of the mGluR signaling pathway were identified by high-throughput multiplex sequencing of pooled samples from 290 non-syndromic autism cases and 300 ethnically matched controls on two independent next-generation platforms. This analysis revealed significant enrichment of rare functional variants in the mGluR pathway in autism cases. Higher burdens of rare, potentially deleterious variants were identified in autism cases for three pathway genes previously implicated in syndromic autism spectrum disorder, TSC1, TSC2, and SHANK3, suggesting that genetic variation in these genes also contributes to risk for non-syndromic autism. In addition, our analysis identified HOMER1, which encodes a postsynaptic density-localized scaffolding protein that interacts with Shank3 to regulate mGluR activity, as a novel autism-risk gene. Rare, potentially deleterious HOMER1 variants identified uniquely in the autism population affected functionally important protein regions or regulatory sequences and co-segregated closely with autism among children of affected families. We also identified rare ASD-associated coding variants predicted to have damaging effects on components of the Ras/MAPK cascade. Collectively, these findings suggest that altered signaling downstream of mGluRs contributes to the pathogenesis of non-syndromic autism.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mutations in several components of the Ras-MAPK pathway have been associated with ASD, including rare mutations in HRAS, MAP2K2 and SYNGAP1, and with syndromes that have ASD features and mutations in NF1, MAP2K1, MAP2K2.
“Mutations in multiple components of this pathway have recently been found to be associated with ASD, including rare mutations in HRAS, MAP2K2 and SYNGAP1, and with syndromes with ASD features (that have mutations in NF1, MAP2K1, MAP2K2)93,94.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 54 · Cited by 116
- Authors
- Kelleher III, R. J., Geigenmüller, U., Hovhannisyan, H., Trautman, E., Pinard, R., Rathmell, B., Carpenter, R., & Margulies, D.
- Affiliations
- Seaside Therapeutics (United States) (US)
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-27
- Volume
- 7
- Issue
- 4
- Pages
- e35003
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3338748
- OpenAlex
- W2113359154
- Cited by
- 116
- References
- 54
- Citations by year
- 2026: 5 · 2025: 4 · 2023: 1 · 2022: 7 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 11 · 2017: 11 · 2016: 8 · 2015: 9 · 2014: 13 · 2013: 18 · 2012: 3
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Autism Speaks
- Simons Foundation
- Simons Foundation Autism Research Initiative
- National Institute of Mental Health (U24MH081810, K02MH087796)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- autism spectrum disorder, rare variants, non-syndromic autism, Homer1, SHANK3, TSC1, TSC2, RAS/MAPK pathway, autism risk genes, deleterious mutations, postsynaptic scaffolding proteins, co-segregation
- MeSH terms
- Homer Scaffolding Proteins, Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Autistic Disorder, Carrier Proteins, Female, Humans, Male, Nerve Tissue Proteins, Risk Factors, Genetic Variation, Signal Transduction, Case-Control Studies, Receptors, Metabotropic Glutamate, Polymorphism, Single Nucleotide, Tumor Suppressor Proteins, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review